Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Cash from Financing Activities (2016 - 2017)

Bone Biologics has reported Cash from Financing Activities over the past 2 years, most recently at $1.4 million for Q3 2017.

  • Quarterly Cash from Financing Activities changed N/A to $1.4 million in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Dec 2017, down 50.24% year-over-year, with the annual reading at $4.7 million for FY2025, 6.26% up from the prior year.
  • Cash from Financing Activities was $1.4 million for Q3 2017 at Bone Biologics, down from $2.0 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $5.6 million in Q1 2016 and troughed at $1.2 million in Q4 2016.